Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 1;63(5):219-23.

[A proposal for a model to replace carbamazepine or oxcarbazepine by eslicarbazepine acetate in clinical practice]

[Article in Spanish]
J J Poza-Aldea  1
Affiliations
  • PMID: 27569568
Review

[A proposal for a model to replace carbamazepine or oxcarbazepine by eslicarbazepine acetate in clinical practice]

[Article in Spanish]
J J Poza-Aldea. Rev Neurol. .

Abstract
in English, Spanish

Introduction: For many years carbamazepine (CBZ) has been the reference drug for the treatment of partial epileptic seizures. However, the problems related with its pharmacokinetics and safety have led to the development of other derivatives, such as oxcarbazepine (OXC) and, more recently, eslicarbazepine acetate (ESL), which do not display these drawbacks.

Development: In clinical practice, the possibility of replacing CBZ or OCX by ESL is a relatively frequent occurrence, the aim being to maintain the efficacy of its predecessors and benefit from the advantages in terms of the pharmacokinetics and safety of this latter derivative. To achieve this, it is essential to have an approximate dose equivalence and exchange protocol. This review offers a practical reasoned model for carrying out the change.

Conclusions: The shift from OXC to ESL can be completed from one day to the next with a dose equivalence of 1-1.5 to 1. Replacement of CBZ by ESL must be more progressive, and the dose equivalence is established as 1-1.3 to 1.

Title: Propuesta de modelo para sustituir carbamacepina u oxcarbacepina por acetato de eslicarbacepina en la practica clinica.

Introduccion. Durante muchos a˜os, la carbamacepina (CBZ) ha sido el farmaco de referencia para el tratamiento de las crisis epilepticas parciales. Sin embargo, los problemas asociados de su farmacocinetica y tolerabilidad han llevado al desarrollo de otros derivados, como la oxcarbacepina (OXC) y, mas recientemente, el acetato de eslicarbacepina (ESL), que obvien estos inconvenientes. Desarrollo. En la practica clinica, se presenta con relativa frecuencia la posibilidad de sustituir la CBZ o la OXC por ESL, buscando mantener la eficacia de los predecesores y ganar las ventajas en el ambito de farmacocinetica y tolerabilidad que ofrece este ultimo derivado. Para ello es indispensable disponer de una equivalencia aproximada de dosis y un protocolo de intercambio. La presente revision ofrece un modelo practico y razonado para realizar el cambio. Conclusiones. El paso de OXC a ESL se puede realizar de un dia para otro con una equivalencia de dosis de 1-1,5 a 1. La sustitucion de CBZ por ESL debe ser mas progresiva, y la equivalencia de dosis se establece en 1-1,3 a 1.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources